There has been no significant breakthrough in the treatment of Systemic Lupus Erythematosus (SLE) for over 50 years. Treatment continues to rely on non-specific immunosuppressant drugs and glucocorticoids (GC, or ‘steroids’), and the impact on patients includes high mortality and poor quality of life. In this proposal, I will validate novel endpoints which will break the impasse in SLE drug development and develop tools for minimising GC use in SLE.
Rogue B Cell Clones In Patients With Autoimmune Disease
Funder
National Health and Medical Research Council
Funding Amount
$916,670.00
Summary
Our immune system protects us from disease by producing antibodies. However, 5% of Australians suffer from an autoimmune disease where they produce “auto” antibodies, which attack their own organs. This research will study the cells (termed B cells) responsible for making autoantibodies to determine how they differ from B cells that defend against disease. The goal is to develop therapies that eliminate autoantibody producing B cells from patients while preserving the immune system.
Exploring The Contribution Of Interferon-lambda To Autoimmune Disease
Funder
National Health and Medical Research Council
Funding Amount
$833,235.00
Summary
We have found that a novel protein, normally made in response to viral infections, is found in the blood of Lupus patients. This project will determine the cells that make this protein, what in Lupus blood makes these cells produce it and whether it plays a role in the severity of Lupus disease.
Targeting Autophagy As A Means Of Control Of Cytokine Production In SLE
Funder
National Health and Medical Research Council
Funding Amount
$616,518.00
Summary
Systemic lupus erythematosus (SLE, or lupus) is a common immune disease that causes organ damage and loss of life, chiefly affecting young women. There is no cure for SLE. We have discovered that a natural process called 'autophagy' could be a way to limit inflammation during SLE. In this project we will discover whether this could lead to a new way to treat this disease.
Optimising Osteoporosis Management In Young Adults
Funder
National Health and Medical Research Council
Funding Amount
$132,743.00
Summary
Fragility fractures contribute to reduced quality of life in younger adults with chronic disease. However, tools for predicting these fractures and evidence for the best treatment to prevent them is lacking in this group. We aim to address these gaps in evidence through assessment of bone health in younger adults with two chronic diseases related to increased inflammation of either the bowel or joints, as they are the two leading conditions resulting in fragility fractures in younger adults.